Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP-AF: Stepwise vs Standard Anticoagulation in CIED Procedures
NCT07616414Not yet recruiting
- Sponsor
- Fuwai Hospital
- Start
- May 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Randomised, open-label trial of edoxaban and rivaroxaban in nonvalvular atrial fibrillation (NVAF) (2 arms), sponsored by Fuwai Hospital. Primary endpoint: Incidence of Clinically Significant Pocket Hematoma at 30 days. Planned start May 2026; status: not yet recruiting.
02
Drugs
edoxabanrivaroxaban
03
Conditions
nonvalvular atrial fibrillation (NVAF)
Beyond the preview
Go deeper on NCT07616414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07616414.